Skip to main content

04.05.2024 | Original Article

Extent of surgery for unilateral papillary thyroid cancer with nonsuspicious contralateral nodules by ultrasound

verfasst von: Siyuan Xu, Hui Huang, Keyao Xian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu

Erschienen in: Endocrine

Einloggen, um Zugang zu erhalten

Abstract

Background

The discussion about surgical treatment of patients with papillary thyroid cancer(PTC) has been an ongoing issue, which is mainly focused on characteristics of tumor, but rarely on nonsuspicious contralateral nodules. We aimed to compare recurrence-free survival(RFS)/progression-free survival(PFS) of unilateral PTC patients with nonsuspicious contralateral nodules after different extents of surgery.

Methods

Unilateral PTC patients with nonsuspicious contralateral nodules underwent surgery from 2015 to 2017 were enrolled. The association between surgical extent and RFS/PFS was analyzed by Kaplan-Meier method and Cox proportional hazards model.

Results

A total of 1293 PTC patients (595[46.0%]TT,523[40.4%]lobectomy+nodule enucleation(LNE),175[13.5%]lobectomy) were analyzed. Patients with a greater surgical extent were more likely to be older, have a greater multifocality of the tumor and contralateral nodules, larger contralateral nodules and primary tumors, and more micro extrathyroidal extension (P < 0.05). After a median follow-up of 45 months, significant growth(>3 mm) was identified in 24 (4.6%) and 19 (10.9%) patients in the LNE and lobectomy group, 7 (1.2%), 14 (2.7%) and 11 (6.3%) structural recurrences and 7 (1.2%), 11 (2.1%) and 7 (4.0%) progression in disease were identified in the TT, LNE and lobectomy groups, respectively. Unadjusted and adjusted RFS/PFS were significantly worse for patients treated with lobectomy than for those who underwent LNE or TT(3-year RFS, 95.5%, 98.2% vs. 99.0%; 3-year PFS, 97.9%, 98.9% vs. 99.0%, P < 0.05), but difference in PFS between LNE and TT lost statistical significance (unadjusted P = 0.226, adjusted P = 0.150).

Conclusions

Due to subtle changes in nodules and acceptable prognosis, lobectomy is a considerable option for unilateral PTC patients with nonsuspicious nodules, when a similar prognosis to TT is expected, LNE may be an effective alternative to optimize quality of life.
Literatur
1.
Zurück zum Zitat M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388(10061), 2783–2795 (2016)CrossRefPubMed M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388(10061), 2783–2795 (2016)CrossRefPubMed
2.
Zurück zum Zitat B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016)CrossRefPubMedPubMedCentral B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016)CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat C. Durante, G. Costante, G. Lucisano et al. The natural history of benign thyroid nodules. JAMA 313(9), 926–935 (2015)CrossRefPubMed C. Durante, G. Costante, G. Lucisano et al. The natural history of benign thyroid nodules. JAMA 313(9), 926–935 (2015)CrossRefPubMed
5.
Zurück zum Zitat A. Ritter, G. Bachar, D. Hirsch et al. Natural history of contralateral nodules after lobectomy in patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 103(2), 407–414 (2018)CrossRefPubMed A. Ritter, G. Bachar, D. Hirsch et al. Natural history of contralateral nodules after lobectomy in patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 103(2), 407–414 (2018)CrossRefPubMed
6.
Zurück zum Zitat F. Pacini, R. Elisei, M. Capezzone et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid 11(9), 877–881 (2001)CrossRefPubMed F. Pacini, R. Elisei, M. Capezzone et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid 11(9), 877–881 (2001)CrossRefPubMed
7.
Zurück zum Zitat B. Ibrahim, V.I. Forest, M. Hier, A.M. Mlynarek, D. Caglar, R.J. Payne, Completion thyroidectomy: predicting bilateral disease. J. Otolaryngol. Head Neck Surg. 44(1), 23 (2015)CrossRefPubMedPubMedCentral B. Ibrahim, V.I. Forest, M. Hier, A.M. Mlynarek, D. Caglar, R.J. Payne, Completion thyroidectomy: predicting bilateral disease. J. Otolaryngol. Head Neck Surg. 44(1), 23 (2015)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat E.S. Kim, T.Y. Kim, J.M. Koh et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin. Endocrinol. 61(1), 145–148 (2004)CrossRef E.S. Kim, T.Y. Kim, J.M. Koh et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin. Endocrinol. 61(1), 145–148 (2004)CrossRef
9.
Zurück zum Zitat B.S. Koo, H.S. Lim, Y.C. Lim et al. Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Ann. Surg. Oncol. 17(4), 1101–1105 (2010)CrossRefPubMed B.S. Koo, H.S. Lim, Y.C. Lim et al. Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Ann. Surg. Oncol. 17(4), 1101–1105 (2010)CrossRefPubMed
10.
Zurück zum Zitat Y.C. Lee, Y.G. Eun, Y.M. Sohn et al. Predictive factors for occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma by preoperative ultrasonographic and pathological features. World J. Surg. 39(7), 1736–1741 (2015)CrossRefPubMed Y.C. Lee, Y.G. Eun, Y.M. Sohn et al. Predictive factors for occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma by preoperative ultrasonographic and pathological features. World J. Surg. 39(7), 1736–1741 (2015)CrossRefPubMed
11.
Zurück zum Zitat L. Lodewijk, W.P. Kluijfhout, J.W. Kist et al. Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1 cm. Langenbecks Arch. Surg. 401(3), 365–373 (2016)CrossRefPubMedPubMedCentral L. Lodewijk, W.P. Kluijfhout, J.W. Kist et al. Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1 cm. Langenbecks Arch. Surg. 401(3), 365–373 (2016)CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat H. Huang, J. Liu, X. Wang, S. Liu, Outcomes of nonsuspicious contralateral nodules with active surveillance after lobectomy in patients with papillary thyroid carcinoma. Front Endocrinol. 13, 941080 (2022)CrossRef H. Huang, J. Liu, X. Wang, S. Liu, Outcomes of nonsuspicious contralateral nodules with active surveillance after lobectomy in patients with papillary thyroid carcinoma. Front Endocrinol. 13, 941080 (2022)CrossRef
13.
Zurück zum Zitat F.N. Tessler, W.D. Middleton, E.G. Grant et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee. J. Am. Coll. Radiol. 14(5), 587–595 (2017)CrossRefPubMed F.N. Tessler, W.D. Middleton, E.G. Grant et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee. J. Am. Coll. Radiol. 14(5), 587–595 (2017)CrossRefPubMed
14.
Zurück zum Zitat T. Ma, H. Wang, J. Liu, J. Zou, S. Liu, Should contralateral nodules be an indication of total or completion thyroidectomy for patients with unilateral papillary thyroid carcinoma? Front Endocrinol. 12, 723631 (2021)CrossRef T. Ma, H. Wang, J. Liu, J. Zou, S. Liu, Should contralateral nodules be an indication of total or completion thyroidectomy for patients with unilateral papillary thyroid carcinoma? Front Endocrinol. 12, 723631 (2021)CrossRef
15.
Zurück zum Zitat R.I. Haddad, L. Bischoff, D. Ball et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 20(8), 925–951 (2022)CrossRefPubMed R.I. Haddad, L. Bischoff, D. Ball et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 20(8), 925–951 (2022)CrossRefPubMed
16.
Zurück zum Zitat L. Lamartina, C. Durante, S. Filetti, D.S. Cooper, Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J. Clin. Endocrinol. Metab. 100(5), 1748–1761 (2015)CrossRefPubMed L. Lamartina, C. Durante, S. Filetti, D.S. Cooper, Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J. Clin. Endocrinol. Metab. 100(5), 1748–1761 (2015)CrossRefPubMed
17.
Zurück zum Zitat E. Ruel, S. Thomas, M. Dinan, J.M. Perkins, S.A. Roman, J.A. Sosa, Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J. Clin. Endocrinol. Metab. 100(4), 1529–1536 (2015)CrossRefPubMedPubMedCentral E. Ruel, S. Thomas, M. Dinan, J.M. Perkins, S.A. Roman, J.A. Sosa, Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J. Clin. Endocrinol. Metab. 100(4), 1529–1536 (2015)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat I.J. Nixon, I. Ganly, S.G. Patel et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23(6), 683–694 (2013)CrossRefPubMed I.J. Nixon, I. Ganly, S.G. Patel et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23(6), 683–694 (2013)CrossRefPubMed
19.
20.
Zurück zum Zitat A. Sugenoya, H. Masuda, M. Komatsu et al. Adenomatous goitre: therapeutic strategy, postoperative outcome, and study of epidermal growth factor receptor. Br. J. Surg. 79(5), 404–406 (1992)CrossRefPubMed A. Sugenoya, H. Masuda, M. Komatsu et al. Adenomatous goitre: therapeutic strategy, postoperative outcome, and study of epidermal growth factor receptor. Br. J. Surg. 79(5), 404–406 (1992)CrossRefPubMed
Metadaten
Titel
Extent of surgery for unilateral papillary thyroid cancer with nonsuspicious contralateral nodules by ultrasound
verfasst von
Siyuan Xu
Hui Huang
Keyao Xian
Xiaolei Wang
Zhengang Xu
Shaoyan Liu
Jie Liu
Publikationsdatum
04.05.2024
Verlag
Springer US
Erschienen in
Endocrine
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03850-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.